Company Overview
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -33.3%, profit CAGR -30.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -33.33% |
| 1 Year: | -100.00% |
Compounded Profit Growth
| 5 Years: | -30.52% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -76.76% |
| 6 Months: | -62.44% |
| 3 Months: | -52.38% |
| 1 Month: | -19.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -33.3% CAGR over 5 years.
- Earnings shrank at -30.5% CAGR over 5 years.
- Trading 79.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XCUR Exicure, Inc. | 1.60 | -1.02 | $10.20M | 0.00% | -54.95% | -145.16% | -33.33% | -30.52% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 3.02M | 2.45M | 2.39M | 2.26M | 1.60M |
| Operating Income | - | -3.02M | -2.45M | -2.39M | -2.26M | -1.60M |
| EBITDA | - | -2.92M | -2.32M | -2.37M | -3.37M | -1.50M |
| Interest Expense | 0 | - | - | 0 | 1.00K | - |
| Pretax Income | - | 3.01M | -2.62M | -2.44M | -3.53M | -1.83M |
| Tax Provision | - | 0 | 0 | 0 | -634.00K | 0 |
| Net Income | - | 3.01M | -2.62M | -2.44M | -2.90M | -1.83M |
| Diluted EPS | - | 0.49 | -0.41 | -0.39 | - | -0.29 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 28.83M | 0 | 500.00K | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 30.66M | 13.14M | 5.45M | 10.12M |
| Operating Income | -1.83M | -13.14M | -4.95M | -10.12M |
| EBITDA | 78.00K | -15.54M | -8.85M | -5.12M |
| Interest Expense | 595.00K | 0 | 18.00K | 1.00K |
| Pretax Income | -2.37M | -16.91M | -9.69M | -5.58M |
| Tax Provision | 209.00K | 0 | 8.00K | -634.00K |
| Net Income | -2.58M | -16.91M | -9.70M | -4.95M |
| Diluted EPS | -2.80 | -10.55 | -4.75 | -0.79 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 23.33M | 11.58M | 15.06M | 14.04M |
| Current Assets | - | 10.05M | 2.02M | 13.67M | 4.62M |
| Cash & Equivalents | - | 8.58M | 816.00K | 12.51M | 3.75M |
| Inventory | - | - | - | - | - |
| Receivables | 0 | - | - | - | - |
| Total Liabilities | - | 8.41M | 8.55M | 8.28M | 10.12M |
| Current Liabilities | - | 1.64M | 2.51M | 3.07M | 3.89M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 7.31M | 6.67M | 5.93M | 176.00K |
| Total Equity | - | 14.92M | 3.03M | 6.77M | 3.93M |
| Shares Outstanding | - | 993.18K | 1.73M | 6.03M | 6.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -35.66M | -10.36M | -2.91M | -8.55M |
| Investing Cash Flow | - | 4.70M | -1.08M | 0 | -1.81M |
| Financing Cash Flow | - | -3.10M | 3.67M | 13.40M | 1.60M |
| Capital Expenditure | -968.00K | -10.00K | - | - | -1.00K |
| Free Cash Flow | - | -35.67M | -10.36M | -2.91M | -8.56M |
| Net Change in Cash | - | -34.07M | -7.76M | 10.49M | -8.76M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -6.4% | - | -989.8% | - |
| Net Margin % | -9.0% | - | -1,940.2% | - |
| ROE % | -17.3% | -558.0% | -143.3% | -126.0% |
| ROCE % | -8.4% | -144.9% | -41.3% | -99.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Carlyle Group Inc. | 0.88% | 56.33K | $90.12K |
| 2 | Geode Capital Management, LLC | 0.58% | 36.91K | $59.06K |
| 3 | Vanguard Capital Management LLC | 0.52% | 32.98K | $52.77K |
| 4 | Vanguard Fiduciary Trust Co | 0.21% | 13.16K | $21.06K |
| 5 | Northern Trust Corporation | 0.17% | 10.69K | $17.10K |
| 6 | Northwestern University | 0.16% | 10.43K | $16.69K |
| 7 | Blackrock Inc. | 0.15% | 9.35K | $14.96K |
| 8 | UBS Group AG | 0.01% | 866 | $1.39K |
| 9 | Tower Research Capital LLC (TRC) | 0.01% | 489 | $782 |
| 10 | Morgan Stanley | - | 158 | $252 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XCUR
XCUR — Frequently Asked Questions
What is the current share price of Exicure, Inc. (XCUR)?
As of 2026-08-02 19:16 PDT, Exicure, Inc. (XCUR) trades at $1.60 on NasdaqCM. Its 52-week range is $1.57 to $7.69.
What is the market capitalisation of XCUR?
Exicure, Inc. (XCUR) has a market capitalisation of $10.20M on NasdaqCM.
What is the P/E ratio of XCUR?
XCUR trades at a trailing price-to-earnings (P/E) ratio of -1.02. The industry average P/E is 27.41. Its price-to-book (P/B) ratio is 4.86.
What is the return on equity (ROE) of XCUR?
XCUR has a return on equity (ROE) of -145.16%. Its return on capital employed (ROCE) is -54.95%.
Is XCUR a good stock to buy?
This page provides a data-driven analysis of Exicure, Inc. (XCUR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.